Cargando…
Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy
Reports on the prognostic role of programmed death-ligand 1 (PD-L1) expression in rectal cancer are controversial. We investigated expression patterns and changes of PD-L1 in rectal cancer patients undergoing neoadjuvant chemoradiotherapy (CRT). Seventy-two patients diagnosed with rectal cancer and/...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563312/ https://www.ncbi.nlm.nih.gov/pubmed/32867256 http://dx.doi.org/10.3390/jcm9092775 |
_version_ | 1783595463004389376 |
---|---|
author | Huemer, Florian Klieser, Eckhard Neureiter, Daniel Schlintl, Verena Rinnerthaler, Gabriel Pagès, Franck Kirilovsky, Amos El Sissy, Carine Iglseder, Wolfgang Singhartinger, Franz Jäger, Tarkan Dinnewitzer, Adam Zaborsky, Nadja Steiner, Markus Greil, Richard Weiss, Lukas |
author_facet | Huemer, Florian Klieser, Eckhard Neureiter, Daniel Schlintl, Verena Rinnerthaler, Gabriel Pagès, Franck Kirilovsky, Amos El Sissy, Carine Iglseder, Wolfgang Singhartinger, Franz Jäger, Tarkan Dinnewitzer, Adam Zaborsky, Nadja Steiner, Markus Greil, Richard Weiss, Lukas |
author_sort | Huemer, Florian |
collection | PubMed |
description | Reports on the prognostic role of programmed death-ligand 1 (PD-L1) expression in rectal cancer are controversial. We investigated expression patterns and changes of PD-L1 in rectal cancer patients undergoing neoadjuvant chemoradiotherapy (CRT). Seventy-two patients diagnosed with rectal cancer and/or treated with fluorouracil-based neoadjuvant CRT at the Department of Internal Medicine III of the Paracelsus Medical University Salzburg (Austria) between January 2003 and October 2012 were included. PD-L1 scoring was performed according to the tumor proportion score (TPS), combined positive score (CPS), and immune cell score (IC). PD-L1 TPS prior to neoadjuvant CRT had a statistically significant impact on survival (median: ≤1%: 95.4 months (95% CI: 51.8—not reached) vs. >1%: not reached, p = 0.03, log-rank). Patients with a PD-L1 TPS ≤1% prior to and after CRT showed an inferior survival compared to all other patients (median: 56.7 months (95% CI: 51.4—not reached) vs. not reached, p = 0.005, log-rank). In multivariate analysis, PD-L1 TPS prior to neoadjuvant CRT (>1% vs. ≤1%, hazard ratio: 0.29 (95% CI: 0.11–0.76), p = 0.01) remained independently associated with survival. In conclusion, low PD-L1 TPS was associated with inferior survival in rectal cancer patients undergoing neoadjuvant CRT. A prospective validation of the prognostic value of PD-L1 expression in rectal cancer patients within a clinical trial is necessitated. |
format | Online Article Text |
id | pubmed-7563312 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75633122020-10-27 Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy Huemer, Florian Klieser, Eckhard Neureiter, Daniel Schlintl, Verena Rinnerthaler, Gabriel Pagès, Franck Kirilovsky, Amos El Sissy, Carine Iglseder, Wolfgang Singhartinger, Franz Jäger, Tarkan Dinnewitzer, Adam Zaborsky, Nadja Steiner, Markus Greil, Richard Weiss, Lukas J Clin Med Article Reports on the prognostic role of programmed death-ligand 1 (PD-L1) expression in rectal cancer are controversial. We investigated expression patterns and changes of PD-L1 in rectal cancer patients undergoing neoadjuvant chemoradiotherapy (CRT). Seventy-two patients diagnosed with rectal cancer and/or treated with fluorouracil-based neoadjuvant CRT at the Department of Internal Medicine III of the Paracelsus Medical University Salzburg (Austria) between January 2003 and October 2012 were included. PD-L1 scoring was performed according to the tumor proportion score (TPS), combined positive score (CPS), and immune cell score (IC). PD-L1 TPS prior to neoadjuvant CRT had a statistically significant impact on survival (median: ≤1%: 95.4 months (95% CI: 51.8—not reached) vs. >1%: not reached, p = 0.03, log-rank). Patients with a PD-L1 TPS ≤1% prior to and after CRT showed an inferior survival compared to all other patients (median: 56.7 months (95% CI: 51.4—not reached) vs. not reached, p = 0.005, log-rank). In multivariate analysis, PD-L1 TPS prior to neoadjuvant CRT (>1% vs. ≤1%, hazard ratio: 0.29 (95% CI: 0.11–0.76), p = 0.01) remained independently associated with survival. In conclusion, low PD-L1 TPS was associated with inferior survival in rectal cancer patients undergoing neoadjuvant CRT. A prospective validation of the prognostic value of PD-L1 expression in rectal cancer patients within a clinical trial is necessitated. MDPI 2020-08-27 /pmc/articles/PMC7563312/ /pubmed/32867256 http://dx.doi.org/10.3390/jcm9092775 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Huemer, Florian Klieser, Eckhard Neureiter, Daniel Schlintl, Verena Rinnerthaler, Gabriel Pagès, Franck Kirilovsky, Amos El Sissy, Carine Iglseder, Wolfgang Singhartinger, Franz Jäger, Tarkan Dinnewitzer, Adam Zaborsky, Nadja Steiner, Markus Greil, Richard Weiss, Lukas Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy |
title | Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy |
title_full | Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy |
title_fullStr | Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy |
title_full_unstemmed | Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy |
title_short | Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy |
title_sort | impact of pd-l1 scores and changes on clinical outcome in rectal cancer patients undergoing neoadjuvant chemoradiotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563312/ https://www.ncbi.nlm.nih.gov/pubmed/32867256 http://dx.doi.org/10.3390/jcm9092775 |
work_keys_str_mv | AT huemerflorian impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy AT kliesereckhard impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy AT neureiterdaniel impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy AT schlintlverena impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy AT rinnerthalergabriel impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy AT pagesfranck impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy AT kirilovskyamos impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy AT elsissycarine impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy AT iglsederwolfgang impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy AT singhartingerfranz impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy AT jagertarkan impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy AT dinnewitzeradam impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy AT zaborskynadja impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy AT steinermarkus impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy AT greilrichard impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy AT weisslukas impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy |